Literature DB >> 34788364

Stability of extemporaneously prepared preservative-free methylphenidate 5 mg/mL intravenous solution.

Megan E Barra1, Brian L Edlow2,3, James T Lund1, Katherine S DeSanctis1, John Vetrano1, Cherylann Reilly-Tremblay1, Edlyn R Zhang4, Yelena G Bodien2,3, Emery N Brown5,6, Ken Solt4.   

Abstract

PURPOSE: To advance the implementation of consciousness-promoting therapies in patients with acute disorders of consciousness, the availability of potential therapeutic agents in formulations suitable for administration in hospitalized patients in the presence of complex comorbid conditions is paramount. The purpose of this study is to evaluate the long-term stability of extemporaneously prepared preservative-free methylphenidate hydrochloride (HCl) 5 mg/mL intravenous solution for experimental use.
METHODS: A methylphenidate 5 mg/mL solution was prepared under proper aseptic techniques with Methylphenidate Hydrochloride, USP, powder mixed in sterile water for solution. Methylphenidate HCl 5 mg/mL solution was sterilized by filtration technique under USP <797>-compliant conditions. Samples were stored refrigerated (2-8°C) and analyzed at approximately days 1, 30, 60, 90, 180, and 365. At each time point, chemical and physical stability were evaluated by visual inspection, pH measurement, membrane filtration procedure, turbidometric or photometric technique, and high-performance liquid chromatography analysis.
RESULTS: Over the 1-year study period, the samples retained 96.76% to 102.04% of the initial methylphenidate concentration. There was no significant change in the visual appearance, pH level, or particulate matter during the study period. The sterility of samples was maintained and endotoxin levels were undetectable throughout the 1-year stability period.
CONCLUSION: Extemporaneously prepared preservative-free methylphenidate 5 mg/mL intravenous solution was physically and chemically stable at 32, 61, 95, 186, and 365 days when stored in amber glass vials at refrigerated temperatures (2-8°C). © American Society of Health-System Pharmacists 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  coma; consciousness; drug stability; injection; methylphenidate; stimulants

Mesh:

Substances:

Year:  2022        PMID: 34788364      PMCID: PMC9013207          DOI: 10.1093/ajhp/zxab420

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.980


  15 in total

1.  Comparison of oral and intravenous methylphenidate.

Authors:  D S Janowsky; P Leichner; P Clopton; L L Judd; D Parker; L Huey
Journal:  Psychopharmacology (Berl)       Date:  1978-09-15       Impact factor: 4.530

2.  Methylphenidate actively induces emergence from general anesthesia.

Authors:  Ken Solt; Joseph F Cotten; Aylin Cimenser; Kin F K Wong; Jessica J Chemali; Emery N Brown
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

Review 3.  ASHP guidelines on compounding sterile preparations.

Authors: 
Journal:  Am J Health Syst Pharm       Date:  2014-01-15       Impact factor: 2.637

4.  Active emergence from propofol general anesthesia is induced by methylphenidate.

Authors:  Jessica J Chemali; Christa J Van Dort; Emery N Brown; Ken Solt
Journal:  Anesthesiology       Date:  2012-05       Impact factor: 7.892

Review 5.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

6.  Methylphenidate and amantadine to stimulate reawakening in comatose patients resuscitated from cardiac arrest.

Authors:  Joshua C Reynolds; Jon C Rittenberger; Clifton W Callaway
Journal:  Resuscitation       Date:  2012-11-21       Impact factor: 5.262

Review 7.  Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis.

Authors:  Chi-Hsien Huang; Chia-Chen Huang; Cheuk-Kwan Sun; Gong-Hong Lin; Wen-Hsuan Hou
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

8.  The Curing Coma Campaign: Framing Initial Scientific Challenges-Proceedings of the First Curing Coma Campaign Scientific Advisory Council Meeting.

Authors:  J Javier Provencio; J Claude Hemphill; Jan Claassen; Brian L Edlow; Raimund Helbok; Paul M Vespa; Michael N Diringer; Len Polizzotto; Lori Shutter; Jose I Suarez; Robert D Stevens; Daniel F Hanley; Yama Akbari; Thomas P Bleck; Melanie Boly; Brandon Foreman; Joseph T Giacino; Jed A Hartings; Theresa Human; Daniel Kondziella; Geoffrey S F Ling; Stephan A Mayer; Molly McNett; David K Menon; Geert Meyfroidt; Martin M Monti; Soojin Park; Nader Pouratian; Louis Puybasset; Benjamin Rohaut; Eric S Rosenthal; Nicholas D Schiff; Tarek Sharshar; Amy Wagner; John Whyte; DaiWai M Olson
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

9.  Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety.

Authors:  Silvia Manrique-Rodríguez; Irene Heras-Hidalgo; M Sagrario Pernia-López; Ana Herranz-Alonso; M Camino Del Río Pisabarro; M Belén Suárez-Mier; M Antonia Cubero-Pérez; Verónica Viera-Rodríguez; Noemí Cortés-Rey; Elizabeth Lafuente-Cabrero; M Carmen Martínez-Ortega; Esther Bermejo-López; Cristina Díez-Sáenz; Piedad López-Sánchez; M Luisa Gaspar-Carreño; Rubén Achau-Muñoz; Juan F Márquez-Peiró; Marta Valera-Rubio; Esther Domingo-Chiva; Irene Aquerreta-González; Ignacio Pellín Ariño; M Cruz Martín-Delgado; Manuel Herrera-Gutiérrez; Federico Gordo-Vidal; Pedro Rascado-Sedes; Emilio García-Prieto; Lucas J Fernández-Sánchez; Sara Fox-Carpentieri; Carlos Lamela-Piteira; Luis Guerra-Sánchez; Miguel Jiménez-Aguado; María Sanjurjo-Sáez
Journal:  Drugs R D       Date:  2020-12-21

10.  Personalized Connectome Mapping to Guide Targeted Therapy and Promote Recovery of Consciousness in the Intensive Care Unit.

Authors:  Brian L Edlow; Megan E Barra; David W Zhou; Andrea S Foulkes; Samuel B Snider; Zachary D Threlkeld; Sourish Chakravarty; John E Kirsch; Suk-Tak Chan; Steven L Meisler; Thomas P Bleck; Joseph J Fins; Joseph T Giacino; Leigh R Hochberg; Ken Solt; Emery N Brown; Yelena G Bodien
Journal:  Neurocrit Care       Date:  2020-08-13       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.